N/A
N=253
Avoidance of Hyperglycaemia in People With Type 1 Diabetes
Diabetes Mellitus, Type 1
Bottom Line
View on ClinicalTrials.gov: NCT04732780 ↗Enrolled (actual)
253
Serious AEs
0.0%
Results posted
Aug 2023
Primary outcome: Primary: Hyperglycaemia Avoidance Scale — 44.6 score on a scale
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- No intervention (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Imperial College London
- Primary completion
- Nov 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Hyperglycaemia Avoidance Scale |
44.6 | — |
| PRIMARY General Anxiety Disorder-7 (GAD-7) |
4 | — |
| PRIMARY Patient Health Questionnaire 9 (PHQ-9) |
5 | — |
| PRIMARY State Trait Anxiety Inventory - Trait Subscale |
42.4 | — |
| PRIMARY Hypoglycaemia Fear Survey 2 - Behaviour Subscale |
17.2 | — |
| PRIMARY Problem Areas in Diabetes 5 |
8 | — |
| PRIMARY Hypoglycaemia Fear Survey 2 - Worry Subscale |
26.1 | — |
Summary
This study aims to learn more about avoidance of hyperglycaemia in adults with type 1 diabetes. People who attend a type 1 diabetes clinic will be invited to complete a number of self-report questionnaires and a survey. A subsection of people who experience avoidance of hyperglycaemia will be invited to take part in an interview in order to gain a more in-depth understanding of this issue.
Eligibility Criteria
Inclusion Criteria
- Type 1 diabetes of at least 6 months duration
Exclusion Criteria
- Inability to understand or write in the English language
- Pregnant women
- Unable to participate in the study due to other factors, as assessed by the Chief Investigators
Data sourced from ClinicalTrials.gov (NCT04732780). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.